| Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia JA Burger, A Tedeschi, PM Barr, T Robak, C Owen, P Ghia, O Bairey, ... New England Journal of Medicine 373 (25), 2425-2437, 2015 | 1738 | 2015 |
| Daratumumab plus lenalidomide and dexamethasone for untreated myeloma T Facon, S Kumar, T Plesner, RZ Orlowski, P Moreau, N Bahlis, S Basu, ... New England Journal of Medicine 380 (22), 2104-2115, 2019 | 901 | 2019 |
| Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma H Quach, D Ritchie, AK Stewart, P Neeson, S Harrison, MJ Smyth, ... Leukemia 24 (1), 22-32, 2010 | 755 | 2010 |
| Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study S Lonial, HC Lee, A Badros, S Trudel, AK Nooka, A Chari, AO Abdallah, ... The lancet oncology 21 (2), 207-221, 2020 | 740 | 2020 |
| Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial S Horwitz, OA O'Connor, B Pro, T Illidge, M Fanale, R Advani, NL Bartlett, ... The Lancet 393 (10168), 229-240, 2019 | 696 | 2019 |
| Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised … M Dimopoulos, H Quach, MV Mateos, O Landgren, X Leleu, D Siegel, ... The Lancet 396 (10245), 186-197, 2020 | 391 | 2020 |
| Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR A Spencer, S Lentzsch, K Weisel, H Avet-Loiseau, TM Mark, I Spicka, ... Haematologica 103 (12), 2079, 2018 | 297 | 2018 |
| Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial P Moreau, MA Dimopoulos, J Mikhael, K Yong, M Capra, T Facon, ... The Lancet 397 (10292), 2361-2371, 2021 | 283 | 2021 |
| Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label … S Grosicki, M Simonova, I Spicka, L Pour, I Kriachok, M Gavriatopoulou, ... The Lancet 396 (10262), 1563-1573, 2020 | 262 | 2020 |
| Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised … T Facon, SK Kumar, T Plesner, RZ Orlowski, P Moreau, N Bahlis, S Basu, ... The Lancet Oncology 22 (11), 1582-1596, 2021 | 229 | 2021 |
| Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group P Moreau, SK Kumar, J San Miguel, F Davies, E Zamagni, N Bahlis, ... The Lancet Oncology 22 (3), e105-e118, 2021 | 212 | 2021 |
| T-cell acute leukaemia exhibits dynamic interactions with bone marrow microenvironments ED Hawkins, D Duarte, O Akinduro, RA Khorshed, D Passaro, M Nowicka, ... Nature 538 (7626), 518-522, 2016 | 204 | 2016 |
| The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy AK Hsu, H Quach, T Tai, HM Prince, SJ Harrison, JA Trapani, MJ Smyth, ... Blood, The Journal of the American Society of Hematology 117 (5), 1605-1613, 2011 | 184 | 2011 |
| Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results AM Lesokhin, MH Tomasson, B Arnulf, NJ Bahlis, H Miles Prince, ... Nature medicine 29 (9), 2259-2267, 2023 | 147 | 2023 |
| A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid®) in subjects with relapsed or refractory … F Morschhauser, O Fitoussi, C Haioun, C Thieblemont, H Quach, ... European journal of cancer 49 (13), 2869-2876, 2013 | 140 | 2013 |
| Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial J Trotman, SF Barrington, D Belada, M Meignan, R MacEwan, C Owen, ... The Lancet Oncology 19 (11), 1530-1542, 2018 | 125 | 2018 |
| Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a … SZ Usmani, H Quach, MV Mateos, O Landgren, X Leleu, D Siegel, ... The Lancet Oncology 23 (1), 65-76, 2022 | 113 | 2022 |
| A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma SJ Harrison, H Quach, E Link, JF Seymour, DS Ritchie, S Ruell, J Dean, ... Blood, The Journal of the American Society of Hematology 118 (24), 6274-6283, 2011 | 96 | 2011 |
| Enumeration, functional responses and cytotoxic capacity of MAIT cells in newly diagnosed and relapsed multiple myeloma NA Gherardin, L Loh, L Admojo, AJ Davenport, K Richardson, A Rogers, ... Scientific reports 8 (1), 4159, 2018 | 94 | 2018 |
| Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE J San-Miguel, H Avet-Loiseau, B Paiva, S Kumar, MA Dimopoulos, ... Blood, The Journal of the American Society of Hematology 139 (4), 492-501, 2022 | 89 | 2022 |
